Clinical Trials

Adult & Pediatric Urology’s strong commitment to clinical research is a result of our belief that research is vital to developing more effective ways to diagnose patients, treat patients, and find life saving cures. We are committed to clinical research as a vital part of advancing the practice of medicine and doing what we can to provide state-of-the-art diagnosis and treatment for the patients we serve.

For more information about clinical trials, please call 320.229.4547 or e-mail us at apuresearch@apumn.com. Thank you.

Currently enrolling for: Benign Prostatic Hyperplasia (Enlarged Prostate) High Grade Prostatic Intrapithelial Neoplasia (PIN) Metastatic Prostate Cancer Newly Diagnosed Prostate Cancer Prostate Cancer on Watchful Waiting Prostate Cancer Patients on Hormonal Therapy Prostate Cancer Prevention Hot Flashes Treatment Overactive Bladder

To view detailed information on completed investigational studies, please click on a topic:

Advanced prostate cancer
Benign prostatic hyperplasia
Bladder cancer
Bone loss prevention for patients with prostate cancer
Erectile dysfunction
Overactive bladder
Prostate cancer
Prostate cancer prevention

---

Advanced Prostate Cancer

• A six-month, open-labeled, fixed-dose study to evaluate the safety, tolerance, pharmacokinetics and endocrine efficacy of two doses of a medication in patients with advanced prostate cancer.

[ back to top ]

Benign Prostatic Hyperplasia

• Prospective, observational registry and patient survey of the management of men with symptomatic benign prostatic hyperplasia

[ back to top ]

Bladder Cancer

• Phase III, randomized, double-blind study of DMFO vs. placebo in low-grade superficial bladder cancer
• Phase II, trial of Intron, Interferon Alpha 2b Plus BCG for treatment of superficial bladder cancer

[ back to top ]

Bone Loss Prevention For Patients With Prostate Cancer

• Phase III, randomized, double-blind, placebo-controlled study to evaluate AMG 162 in the treatment of bone loss in subjects undergoing Androgen-Deprivation Therapy for non-metastatic prostate cancer

[ back to top ]

Erectile Dysfunction

• A Phase III efficacy and safety study of three fixed doses of ED drug versus placebo in the treatment of male erectile dysfunction
• A Phase III, two year, long-term, open-label, flexible dose, safety extension study of ED drug in the treatment of erectile dysfunction
• A Phase III, at-home use study evaluating the efficacy and safety of escalating doses of ED drug in the treatment of patients with erectile dysfunction
• A Phase III study, evaluating the safety and efficacy of ED drug compared to another brand ED drug in the treatment of male erectile dysfunction
• Phase III study, six month, long term, open-label, flexible dose, safety extension study of ED medication in the treatment of erectile dysfunction

[ back to top ]

Overactive Bladder

• Double-blind, multi-center, international, randomized, placebo-controlled study of safety and efficacy of Trospium chloride 60mg modified release capsules vs. placebo, once daily, for 12 weeks followed by a 9-month, open-label treatment phase in patients with overactive bladder
• Open label, parallel-group, multi-center study to evaluate the efficacy, safety and tolerability of Enablex alone or in combination with behavioral modification program for symptoms of overactive bladder
• Phase II, 12-week, randomized, double-blind multi-center study to evaluate the efficacy of darifenacin vs. placebo
• A phase four, multi-center, naturalistic, open-label, observational study, over 12 weeks of patients initiating a medication for overactive bladder

[ back to top ]

Prostate Cancer

• Cancer of the prostate strategic urologic research endeavor (CaPSURE™) a longitudinal observational study of prostate cancer patients nationwide
• An eight-month, open-labeled, fixed-dose study to evaluate the safety, tolerance, pharmacokinetics and endocrine efficacy of two doses of a medication in patients with prostate cancer

[ back to top ]

Prostate Cancer Prevention

• Phase III, randomized, double-blind, placebo-controlled, parallel group study of the efficacy and safety of dutasteride to reduce the risk of biopsy-detectable prostate cancer

[ back to top ]

---

Adult & Pediatric Urology, P.L.L.P
www.apumn.com

Main Office
2351 Connecticut Ave South
Suite 200
Sartell, MN 56377
Tel: 320.259.1411
Fax: 320.259.8967
Toll-free: 888.559.1411

[ map ]

Buffalo Office
1700 Highway 25 North
Suite 120
Buffalo, MN 55313
Tel: 763.682.2268

[ map ]

Research Office
320.229.4547

(and 14 outreach clinics)